Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

3ZRF

pVHL54-213-EloB-EloC complex_apo

Summary for 3ZRF
Entry DOI10.2210/pdb3zrf/pdb
Related1LM8 1LQB 1VCB 2C9W 2IZV 2XAI 3ZRC
DescriptorTRANSCRIPTION ELONGATION FACTOR B POLYPEPTIDE 2, TRANSCRIPTION ELONGATION FACTOR B POLYPEPTIDE 1, VON HIPPEL-LINDAU DISEASE TUMOR SUPPRESSOR,, ... (4 entities in total)
Functional Keywordstranscription, tumour supressor protein, chronic aneamia treatment, e3 ubiquitin ligase
Biological sourceHOMO SAPIENS
More
Cellular locationNucleus (Probable): Q15370 Q15369
Isoform 1: Cytoplasm. Isoform 3: Cytoplasm: P40337
Total number of polymer chains12
Total formula weight171851.34
Authors
Van Molle, I.,Buckley, D.L.,Crews, C.M.,Ciulli, A. (deposition date: 2011-06-16, release date: 2012-03-07, Last modification date: 2023-12-20)
Primary citationBuckley, D.L.,Van Molle, I.,Gareiss, P.C.,Tae, H.S.,Michel, J.,Noblin, D.J.,Jorgensen, W.L.,Ciulli, A.,Crews, C.M.
Targeting the Von Hippel-Lindau E3 Ubiquitin Ligase Using Small Molecules to Disrupt the Vhl/Hif-1Alpha Interaction
J.Am.Chem.Soc., 134:4465-, 2012
Cited by
PubMed Abstract: E3 ubiquitin ligases, which bind protein targets, leading to their ubiquitination and subsequent degradation, are attractive drug targets due to their exquisite substrate specificity. However, the development of small-molecule inhibitors has proven extraordinarily challenging as modulation of E3 ligase activities requires the targeting of protein-protein interactions. Using rational design, we have generated the first small molecule targeting the von Hippel-Lindau protein (VHL), the substrate recognition subunit of an E3 ligase, and an important target in cancer, chronic anemia, and ischemia. We have also obtained the crystal structure of VHL bound to our most potent inhibitor, confirming that the compound mimics the binding mode of the transcription factor HIF-1α, a substrate of VHL. These results have the potential to guide future development of improved lead compounds as therapeutics for the treatment of chronic anemia and ischemia.
PubMed: 22369643
DOI: 10.1021/JA209924V
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.8 Å)
Structure validation

226707

건을2024-10-30부터공개중

PDB statisticsPDBj update infoContact PDBjnumon